PDF下载 ( 359 KB)
Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus ( 2018)
-
摘要:
<正>肝细胞癌(以下简称肝癌)在全球恶性肿瘤发病率排第6位,每年新发的肝癌病例和死亡病例有一半以上发生在中国[1]。我国有肿瘤登记地区的最新数据表明,肝癌发病率居恶性肿瘤第4位,病死率居恶性肿瘤第3位[2]。随着现代医学科技的发展,肝癌的治疗取得了巨大进步。因早期肝癌临床症状并不明显,70%～80%患者就诊时病情已为进展期。目前,肝癌治疗的总体预后仍不理想。由于肝癌的生物学特性和肝脏解剖学特点,肝癌细胞易侵
-
[1]TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65 (2) :87-108. [2]CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66 (2) :115-132. [3]ZHANG ZM, LAI EC, ZHANG C, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus[J]. Int J Surg, 2015, 20:8-16. [4]PAWARODE A, VORAVUD N, SRIURANPONG V, et al. Natural history of untreated primary hepatocellular carcinoma:a retrospective study of 157 patients[J]. Am J Clin Oncol, 1998, 21 (4) :386-391. [5]LI SH, WEI W, GUO RP, et al. Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors[J]. Med Oncol, 2013, 30 (4) :696. [6]LI SH, GUO ZX, XIAO CZ, et al. Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection[J]. Asian Pac J Cancer Prev, 2013, 14 (8) :4759-4763. [7]European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69 (1) :182-236. [8]National Collaborative Group on Diagnosis and Treatment of Hepatocellular Carcinoma Complicated with Tumor Thrombus.Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma complicated with portal vein tumor thrombus (2016 Edition) [J]. Chin J Pract Surg, 2016, 36 (5) :475-480. (in Chinese) 全国肝癌合并癌栓诊治研究协作组.肝细胞癌合并门静脉癌栓多学科诊治中国专家共识 (2016年版) [J].中国实用外科杂志, 2016, 36 (5) :475-480. [9]RYDER SD, British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults[J]. Gut, 2003, 52 (Suppl 3) :1-8. [10]U. S. Preventive Services Task Force. Grade definitions and suggestions for practice[EB/OL].[2018-12-28]. http://www. uspreventiveservicestaskforce. org/Page/Name/grade-definitions. [11]IKAI I, YAMAMOTO Y, YAMAMOTO N, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins[J]. Surg Oncol Clin N Am, 2003, 12 (1) :65-75. [12]CHENG SQ, WU MC, CHEN H, et al. A study on imagination features of tumor thrombi in the portal vein of primary liver cancer[J]. Chin J Gen Surg, 2004, 19 (4) :200-201. (in Chinese) 程树群, 吴孟超, 陈汉, 等.肝癌门静脉癌栓分型的影像学意义[J].中华普通外科杂志, 2004, 19 (4) :200-201. [13] SHUQUN C, MENGCHAO W, HAN C, et al. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein[J]. Hepatogastroenterology, 2007, 54 (74) :499-502. [14]SHI J, LAI EC, LI N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2010, 17 (8) :2073-2080. [15]SHI J, LAI EC, LI N, et al. A new classification for hepatocellular carcinoma with portal vein tumor thrombus[J]. J Hepatobiliary Pancreat Sci, 2011, 18 (1) :74-80. [16]NIU ZJ, MA YL, KANG P, et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus:Using a new classification[J]. Med Oncol, 2012, 29 (4) :2992-2997. [17] WANG K, GUO WX, CHEN MS, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus:a large-scale, multicenter, propensity mathching score analysis[J]. Medicine (Baltimore) , 2016, 95 (11) :e3015. [18] PENG ZW, GUO RP, ZHANG YJ, et al. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Cancer, 2012, 118 (19) :4725-4736. [19]LIANG L, CHEN TH, LI C, et al. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. HPB (Oxford) , 2018, 20 (12) :1119-1129. [20]YU JI, CHOI GS, LIM DH, et al. Treatment of naīve HCC combined with segmental or subsegmental portal vein tumor thrombosis:Liver resection versus TACE followed by radiotherapy[J]. Anticancer Res, 2018, 38 (8) :4919-4925. [21]CHEN XP, QIU FZ, WU ZD, et al. Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma[J]. Ann Surg Oncol, 2006, 13 (7) :940-946. [22]CAO JY, WANG ZS, WU SK, et al. Analysis of surgical treatment and prognostic factors for hepatocellular carcinoma with portal vein tumor thrombus[J]. Transl Cancer Res, 2017, 6 (1) :247-253. [23]CHOK KS, CHEUNG TT, CHAN SC, et al. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis[J]. World J Surg, 2014, 38 (2) :490-496. [24] LI N, FENG S, XUE J, et al. Hepatocellular carcinoma with main portal vein tumor thrombus:A comparative study comparing hepatectomy with or without neoadjuvant radiotherapy[J]. HPB (Oxford) , 2016, 18 (6) :549-556. [25]PENG BG, HE Q, LI JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Am J Surg, 2009, 198 (3) :313-318. [26]FAN J, ZHOU J, WU ZQ, et al. Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis[J]. World J Gastroenterol, 2005, 11 (8) :1215-1219. [27]HATANO E, UEMOTO S, YAMAUE H, et al. Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk:A project study for hepatic surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery[J]. J Hepatobiliary Pancreat Sci, 2018, 25 (9) :395-402. [28]YOSHIDOME H, TAKEUCHI D, KIMURA F, et al. Treatment strategy for hepatocellular carcinoma with major portal vein or inferior vena cava invasion:a single institution experience[J].J Am Coll Surg, 2011, 212 (5) :796-803. [29]BAI T, CHEN J, XIE ZB, et al. The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus[J]. Onco Targets Ther, 2016, 9:3841-3848. [30]CHOI JH, CHUNG WJ, BAE SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. Hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2018, 82 (3) :469-478. [31]LYU N, KONG Y, MU L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69 (1) :60-69. [32]CHUNG GE, LEE JH, KIM HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 258 (2) :627-634. [33]AJIT Y, SUDARSAN H, SAUMYA G, et al. Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein thrombosis:A perspective on survival[J]. Oman Med J, 2014, 29 (6) :430-436. [34]XUE TC, XIE XY, ZHANG L, et al. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus:a meta-analysis[J]. BMC Gastroenterol, 2013, 13:60. [35]CHERN MC, CHUANG VP, LIANG CT, et al. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion:Safety, efficacy, and prognostic factors[J]. J Vasc Interv Radiol, 2014, 25 (1) :32-40. [36]GORODETSKI B, CHAPIRO J, SCHERNTHANER R, et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis:Conventional versus drug-eluting beads transcatheter arterial chemoembolization[J]. Eur Radiol, 2017, 27 (2) :526-535. [37]YOON SM, RYOO BY, LEE SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion:A randomized clinical trial[J]. JAMA Oncol, 2018, 4 (5) :661-669. [38]WANG MH, JI Y, ZENG ZC, et al. Impact factors for microinvasion in patients with hepatocellular carcinoma:Possible application to the definition of clinical tumor volume[J]. Int J Radiat Oncol Biol Phys, 2010, 76 (2) :467-476. [39] XI M, ZHANG L, ZHAO L, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis[J]. PLo S One, 2013, 8 (5) :e63864. [40]HOU JZ, ZENG ZC, WANG BL, et al. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT[J].Jpn J Clin Oncol, 2016, 46 (4) :357-362. [41]LIANG SX, ZHU XD, XU ZY, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma:The risk factors and hepatic radiation tolerance[J]. Int J Radiat Oncol Biol Phys, 2006, 65 (2) :426-434. [42]FENG M, SURESH K, SCHIPPER MJ, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage:A phase 2 clinical trial[J].JAMA Oncol, 2018, 4 (1) :40-47. [43] LI XL, GUO WX, HONG XD, et al. Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus:A propensity score analysis[J]. Hepatol Res, 2016, 46 (11) :1088-1098. [44]LI X, GUO W, GUO L, et al. Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study[J]. Oncotarget, 2018, 9 (36) :24537-24547. [45]YANG M, FANG Z, YAN Z, et al. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone:A twoarm, randomised clinical trial[J]. J Cancer Res Clin Oncol, 2014, 140 (2) :211-219. [46]ZHANG ZH, ZHANG W, GU JY, et al. Treatment of hepatocellular carcinoma with tumor thrombus with the use of iodine-125 seed strand implantation and transarterial chemoembolization:a propensity-score analysis[J]. J Vasc Interv Radiol, 2018, 29 (8) :1085-1093. [47]JIA Z, JIANG G, TIAN F, et al. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Saudi J Gastroenterol, 2016, 22 (5) :353-359. [48]YIN J, LI N, HAN Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma:A twostage longitudinal clinical study[J]. J Clin Oncol, 2013, 31 (29) :3647-3655. [49]Expert Panel of Antiviral Therapy for Hepatocellular Carcinoma.Expert consensus on antiviral therapy to hepatitis B/C virusrelated hepatocellular carcinoma[J]. J Clin Hepatol, 2014, 30 (5) :390-395. (in Chinese) 肝细胞癌抗病毒治疗专家组. HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J].临床肝胆病杂志, 2014, 30 (5) :390-395. [50]BRUIX J, RAOUL JL, SHERMAN M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma:subanalyses of a phase III trial[J]. J Hepatol, 2012, 57 (4) :821-829. [51]KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391 (10126) :1163-1173. [52] ZHU K, CHEN J, LAI L, et al. Hepatocellular carcinoma with portal vein tumor thrombus:treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study[J]. Radiology, 2014, 272 (1) :284-293. [53]GIORGIO A, MEROLA MG, MONTESARCHIO L, et al. Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein:A western randomized controlled trial[J]. Anticancer Res, 2016, 36 (11) :6179-6183. [54]BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) :A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2016, 389 (10064) :56-66. [55]QIN S, BAI Y, LIM HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31 (28) :3501-3508. [56]GOYAL L, ZHENG H, ABRAMS TA, et al. A Phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res, 2018.[Epub ahead of print] [57]CHEN ZW, LIN ZY, CHEN YP, et al. Clinical efficacy of endovascular radiofrequency ablation in the treatment of portal vein tumor thrombus of primary hepatocellular carcinoma[J]. J Cancer Res Ther, 2018, 14 (1) :145-149. [58]LU ZH, SHEN F, YAN ZL, et al. Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation[J]. J Cancer Res Clin Oncol, 2009, 135 (6) :783-789. [59]LU J, GUO JH, ZHU HD, et al. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma:A single-center experience[J]. J Vasc Interv Radiol, 2017, 28 (6) :786-794. [60]Group of Portal Hypertension, Society of Surgery, Chinese Medical Association. Expert consensus on diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension (2015) [J]. Chin J Pract Surg, 2015, 35 (10) :1086-1090. (in Chinese) 中华医学会外科学分会.门静脉高压症学组.肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识 (2015) [J].中国实用外科杂志, 2015, 35 (10) :1086-1090. [61] CHEN Q, SHU C, LAURENCE AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC:A multicentre, randomised clinical trial[J]. Gut, 2018, 67 (11) :2006-2016. -
本文二维码
计量
- 文章访问数: 552
- HTML全文浏览量: 39
- PDF下载量: 761
- 被引次数: 0
下载:
